Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27552962 | 0.81 | CA2 (0.38) | KCNA5CA2KDM4EHPGDALDH1A1 | |
| SCHEMBL18477544 | 0.80 | CA2 (0.34) | KCNA5CA2KDM4EHPGDALDH1A1 | |
| SCHEMBL443530 | 0.80 | CA12 (0.55) | CA2CA12CA1CA4CA7 | |
| SCHEMBL29709902 | 0.80 | CA12 (0.55) | CA2CA12CA1CA4CA7 | |
| SCHEMBL25673267 | 0.80 | CA2 (0.52) | CA2KDM4EHPGDALDH1A1ATM | |
| SCHEMBL2949842 | 0.76 | LMNA (0.43) | CA2CA12CA1CA4CA7 | |
| SCHEMBL29771456 | 0.76 | CA2 (0.57) | CA2CA12CA1CA4CA7 | |
| SCHEMBL142899 | 0.76 | CA2 (0.57) | CA2CA12CA1CA4CA7 | |
| SCHEMBL6690123 | 0.75 | CA2 (0.44) | CA2CA12CA1CA4CA7 | |
| SCHEMBL8733235 | 0.75 | CA2 (0.44) | CA2CA12CA1CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20220389021-A1 | INHIBITORS OF KRAS G12C | BEONE MEDICINES I GMBH (CH) | 2022-12-08 | — | — | US | disclosed |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | KCNA5 2895/4885CA2 324/4885CA12 3164/4885 |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | KRAS, NRAS, HRAS | KCNA5 3173/4885CA2 1854/4885CA12 2473/4885 |
| US-20220389021-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KCNA5 4558/4885CA2 2967/4885CA12 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.